Interview with Oleg Epstein, General Director, Materia Medica
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
Address: 9 bld, 3rd Samotyochnyi per., Moscow, 127 473,Russia
Tel: +7 495 684 43 33
Web: http://www.materiamedica.ru/ru/
Research and manufacturing company Materia Medica Holding is one of the top Russian pharmaceutical companies. For more than 10 years Materia Medica Holding has been carrying out fundamental research in the pharmacology of ultra low doses and currently the company holds the leading position in this field. The researchers of the Company were the first to conduct systemic studies of ultra dilute solutions.
Company’s product portfolio includes OTC drugs of different pharmacological groups, such as immunomodulators, antiviral products and anti-inflammatory drugs(Anaferon for children, Anaferon, Ergoferon), sedative drugs, nootropics and stress – protective drugs (Tenoten, Tenoten for children), weight reduction drugs (Dietressa), regulators of the urogenital system and reproductive system functions(Afala, Impaza), the drugs for treatment of diseases of joints (Arthrofoon), and of alcohol addiction (Proproten-100). The products are marketed in Russia, the CIS countries, Europe, Asia and Latin America. The Company is constantly searching for new areas where the drugs containing ultra low doses of antibodies can be used.
The efforts of the company’s staff for development and introduction into medical practice of new highly effective remedies based on ultra low doses of antibodies to endogenous regulators were recognized with Science & Technology Award 2005 and Science & Technology Award 2006 by Government of the Russia (orders of the Government of the Russia No. 96 dd. February 20th , 2006 AND No. 12 dd. February 22nd , 2007).
The staff of Materia Medica Holding exceeds 600 people. The company has its own production site in Chelyabinsk equipped with the up-to-date GMP-compliant facilities of European manufacturers.
Materia Medica Holding actively carries on cooperation with the leading Russian and foreign research institutions aimed at conducting new studies and to obtaining clinical data.
Materia Medica Holding drugs have become known not only in Russia but also abroad. In many countries marketing authorizations for our drugs have been issued. At present the Company has expanded its activity on FSU, Europe, Asia and Latin America markets. Our affiliate company as well as our representative offices in Belarus, Uzbekistan and Kazakhstan carries out our products presentation.
We strive for developing highly efficient drugs ensuring effective treatment, prophylaxis and rehabilitation in different areas of medicine. We are sure that our drug can help millions of people to protect their health.
Currently, Materia Medica Holding manufactures more than thirty drugs and 8 of them are original products:
Anaferon — an effective drug for prevention and treatment of influenza and SARS.
Anaferon for children— the product was specially developed for treatment and prevention of influenza, SARS and other viral infections in children.
Arthrofoon — a drug for course treatment of chronic inflammatory diseases of joints (rheumatic arthritis, osteoarthritis).
Afala — a drug for treatment of prostatitis and benign prostate hyperplasia (BHP). It reduces oedema and inflammation in tissues, improves prostate functioning.
Impaza — a product for course treatment of erectile dysfunction of different etiology, increases libido and erection.
Proproten-100 — a drug used for treatment of alcoholism, reduces desire to drink and improves withdrawal symptoms. The drug efficiently eliminates the main withdrawal symptoms such as faintness, weakness, tremor, shiver, headache, irritability and insomnia.
Tenoten — it is recommended in case of acute and chronic stresses and neurosis-like conditions. It causes no drowsiness during the day, removes anxiety, and improves memory and attention.
Tenoten for children – t is recommended for children, for the treatment of Attention deficit hyperactivity disorder (ADHD).
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here
